and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil
As part of the settlement, the pharmaceutical company is admitting to promoting the drugs Paxil
and Wellbutrin for off-label uses and failing to report safety data about Avandia to the Food and Drug Administration.
The company pleaded guilty to two counts of introducing misbranded antidepressant drugs Paxil
and Wellbutrin and one charge of failing to report safety data about the diabetes drug Avandia to the Food and Drug Administration (FDA).
Glaxo Plans Huge Liability Charge on Avandia, Paxil
A new study suggests that the antidepressant paroxetine, or Paxil
, fights depression more effectively when it first modifies two personality traits.
A Philadelphia federal district court has ruled that a failure-to-warn lawsuit brought by the parents of a teenager who committed suicide while taking the antidepressant Paxil
is not preempted by federal law.
Families of adolescents who took paroxetine (Paxil
) and attempted suicide have filed suit against GlaxoSmithKline in federal court, claiming that the drugmaker "defrauded the medical profession, the Paxil
patient population, and the general public.
PHILADELPHIA - The maker of the antidepressant Paxil
agreed to pay $14 million to states to settle allegations that it blocked generic versions of the drug from being made, causing the states to pay higher prices.
GlaxoSmithKline has been in the news repeatedly in the past few years for an ever-growing number of scandals, including hiding trials of Paxil
, testing drugs on babies, and illegally overpricing AIDS medications in Africa.
The documents that build the case were filed into the public record by GlaxoSmithKline's lawyers on June 23, 2004 (docket numbers 290 and 291) in the In re Paxil
Products Liability Litigation MDL 1574.
labeling changes will be in the pregnancy subsection of the "precautions" section of the labels for Paxil
The firm recently reintroduced anti-depressant Paxil
CR after it was withdrawn amid fears over its quality - but analyst Jeremy Batstone at stockbroker Charles Stanley said its return came too late to affect Thursday's interim results.